Relapsed Epithelial Ovarian Cancer Clinical Trial
Official title:
A Phase 1b, Open-label, Non-randomized Multicenter Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer
This is a dose escalation study in female subjects with relapsed ovarian cancer (including
epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer).
Approximately 30 to 40 subjects will be administered a combination of conatumumab and
birinapant.
In the initial dose-escalation stage of the study, adult female subjects will receive
conatumumab in combination with increasing doses of birinapant in dose-escalation cohorts to
determine the MTD of birinapant when administered with a fixed dose of conatumumab.
In safety expansion stage, adult female subjects will receive conatumumab in combination
with birinapant at the MTD of the combination.
n/a
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment